^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:dianhydrogalactitol (VAL-083) (Alkylating agent, BRD4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Kintara Therapeutics Press Release
    Title:

    Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma

    Published date:
    06/15/2022
    Excerpt:
    Kintara Therapeutics, Inc. (Nasdaq: KTRA)...today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's VAL-083 for the treatment of patients with newly-diagnosed unmethylated glioblastoma (GBM).
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Kintara Therapeutics Press Release
    Title:

    DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

    Published date:
    12/26/2017
    Excerpt:
    DelMar Pharmaceuticals...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company's lead product candidate, VAL-083, in recurrent glioblastoma (rGBM).